Besse B et al. HUDSON: An open-label, multi-drug, biomarker-directed, Phase II platform study in patients with NSCLC, who progressed on anti-PD(L)1 therapy. WCLC 2022;Abstract OA15.05.
Blackhall F. Immunotherapy in the current management of SCLC. ESMO 2022;Abstract.
Doi T et al. DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study. ESMO 2022;Abstract 4530.
Garassino MC et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the Phase 3 KEYNOTE-189 study. J Clin Oncol 2023;41(11):1992-8. Abstract
Herbst RS et al. COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol 2022;40(29):3383-93. Abstract
Johnson ML et al. Durvalumab (D) ± tremelimumab (T) + chemotherapy (ct) in 1L metastatic (m) NSLCL: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y). ESMO 2022;Abstract LBA59.
Johnson ML et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The Phase III POSEIDON study. J Clin Oncol 2023;41(6):1213-27. Abstract
Kotecha R et al. KEYNOTE B36: A pilot study of first-line tumor treating fields (150 kHz) plus pembrolizumab for advanced or metastatic NSCLC. WCLC 2022;Abstract EP08.01-076.
Levy B et al. TROPION-Lung02: Initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. WCLC 2022;Abstract MA13.07.
Mun EJ et al. Tumor-treating fields: A fourth modality in cancer treatment. Clin Cancer Res 2018;24(2):266-75. Abstract
O’Brien M et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23(10):1274-86. Abstract
Paz-Ares L et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small cell lung cancer: An open-label, phase I study. J Clin Oncol 2023;[Online ahead of print]. Abstract
Paz-Ares L et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7(2):1-8. Abstract
Paz-Ares L et al. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. ESMO Virtual Plenary 2022;Abstract.
Pless M et al. A phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. JAMA 2015;314(23):2535-43. Abstract
Reck M et al. Brief report: Exploratory analysis of maintenance therapy in patients with extensive-stage SCLC treated first line with atezolizumab plus carboplatin and etoposide. J Thorac Oncol 2022;17(9):1122-9. Abstract
Ricordel C et al. Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). ASCO 2022;Abstract 9039.